Iovance Biotherapeutics, Inc. IOVA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s total liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported total liabilities of $203.91M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s total liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total liabilities increased by 2.5% year-over-year, from $198.88M to $203.91M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total liabilities has grown at a 13.9% compound annual growth rate (CAGR), from $111.96M to $214.59M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.